Esophageal Squamous Cell CarcinomaNCT07488624
Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
An observational study of Esophageal Squamous Cell Carcinoma, run by Sichuan University at 3 sites in China.
Trial summary
The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Esophageal Squamous Cell Carcinoma
- How many people
- 414 participants
- Where
- 3 sitesChina
- Study dates
- 1 Mar 2026to 1 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population was drawn from patients with esophageal squamous cell carcinoma treated at West China Hospital, Sichuan University; Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University); and Suining Central Hospital between 2019 and 2025. Patients received neoadjuvant chemoimmunotherapy followed by esophagectomy as part of routine clinical care.
Who may be able to join
- Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy
Who cannot join
- History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data
Trial locations and contacts
3 sites in 1 country.
China3 sites
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041
Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University)
Mianzhu, Sichuan, 618200
Suining Central Hospital
Suining, Sichuan, 629000
About this study
Official title: Development and Internal Validation of a Clinicopathologic Prognostic Model for Overall Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy and Esophagectomy: A Multicenter Retrospective Cohort Study
The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy.
Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.
- Conditions
- Esophageal Squamous Cell Carcinoma
- Medical subject headings
- Esophageal Squamous Cell Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| ESCC Cohort After Neoadjuvant Chemoimmunotherapy and Esophagectomy | This cohort includes patients aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma who received at least one cycle of neoadjuvant chemoimmunotherapy followed by esophagectomy. Patients were treated at three participating medical centers between 2019 and 2025. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up.
Measured: From the date of esophagectomy to death or last follow-up, up to 73 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Mar 2026
- Study start1 Mar 2026
- Primary completion1 Jun 2026
- Study completion1 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Esophageal Squamous Cell CarcinomaStudies of the same condition, open and under way.
- More trials run by Sichuan UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 414 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sichuan University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zhen-Yu Ding, Sichuan University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07488624
- Sponsor's protocol ID
- 2026-Review-263
- Status last verified
- Aug 2026
- First submitted
- 9 Mar 2026
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 13 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Internal Validation of a Clinicopathologic Prognostic Model for Overall Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy and Esophagectomy: A Multicenter Retrospective Cohort Study
- ClinicalTrials.gov ID
- NCT07488624
- Acronym / sponsor ID
- 2026-Review-263
- Conditions
- Esophageal Squamous Cell Carcinoma
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 414 participants (actual)
- Lead sponsor
- Sichuan UniversityUniversity, hospital or other
- Study start
- 1 Mar 2026 (actual)
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 1 Jun 2026 (actual)
- First posted
- 23 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy.
Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| ESCC Cohort After Neoadjuvant Chemoimmunotherapy and Esophagectomy | – | –This cohort includes patients aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma who received at least one cycle of neoadjuvant chemoimmunotherapy followed by esophagectomy. Patients were treated at three participating medical centers between 2019 and 2025. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population was drawn from patients with esophageal squamous cell carcinoma treated at West China Hospital, Sichuan University; Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University); and Suining Central Hospital between 2019 and 2025. Patients received neoadjuvant chemoimmunotherapy followed by esophagectomy as part of routine clinical care.
Key inclusion criteria (1 listed)
- Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy
Key exclusion criteria (1 listed)
- History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Overall Survival (OS)
Time frame: From the date of esophagectomy to death or last follow-up, up to 73 months.
Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Aug 2026.
Related trials for Esophageal Squamous Cell Carcinoma
RecruitingObservational study
Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection
Superficial Esophageal Cancer, Oesophageal Adenocarcinoma
RecruitingPhase 2
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma
RecruitingPhase 1
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Advanced/Metastatic Solid Tumors, Bladder Cancer
Recruiting
Individually Tailored, Supervised, Remote Exercise Intervention to Improve Physical Function for Stage I-III Gastroesophageal Cancer Survivors, PRECISE Trial
Clinical Stage I Esophageal Adenocarcinoma American Joint Committee on Cancer (AJCC) v8, Clinical Stage I Esophageal Squamous Cell Carcinoma AJCC v8
Not yet recruitingObservational study
Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma
Esophageal Squamous Cell Carcinoma (ESCC), Esophageal Fistula
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
3 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Esophageal Squamous Cell Carcinoma, run by Sichuan University at 3 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 3 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: From the date of esophagectomy to death or last follow-up, up to 73 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026; AzTrials last refreshed its copy on 7 Nov 2026.